stockrowUpstream Bio, Inc.
UPBUpstream Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, up 20.4% from fiscal 2024.
- Revenue
- −17.5%
- EPS
- +1.35%
- Free cash flow
- +9.33%
Quarter to June 2026, against a year earlier
Follow UPB
Alert me
Upstream Bio, Inc. (UPB) Return on invested capital
Upstream Bio, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −1,100.9%, down 1100.9 percentage points from fiscal 2025 (0.00%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| WHWK Whitehawk Therapeutics, Inc. compare | 0.00% |
| CGEN Compugen Ltd. compare | 0.00% |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | −127.7% |
| ACOG Alpha Cognition Inc. compare | −144.7% |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −279.8% |
| IVVD Invivyd, Inc. compare | −334.9% |
| UPB Upstream Bio, Inc. | −1,100.9% |
| TRDA Entrada Therapeutics, Inc. compare | −2,009.0% |
| MDWD MediWound Ltd. compare | −6,551.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)